Speciality: Oncology
Description:
A warm welcome to all the medical professionals in this interesting session on understanding the current scenario of blood cancer. Genomic testing and advancements in diagnosis and treatment have revolutionized the field, moving beyond traditional methods to embrace a new era of personalized medicine. Comprehensive molecular profiling, often through Next-Generation Sequencing (NGS), is now a cornerstone of modern hematology. It allows clinicians to identify the specific genetic alterations and mutations that drive an individual's blood cancer, enabling more precise and effective diagnostic classifications and prognoses. This detailed genomic information is critical for guiding treatment decisions and selecting the most appropriate therapeutic strategies.
Building on these genomic insights, there have been remarkable advancements in treatment modalities. Targeted therapies, which are designed to block the proteins or pathways that mutated genes use to promote cancer growth, have emerged as a powerful alternative to conventional chemotherapy. In addition, cutting-edge immunotherapies like CAR T-cell therapy and bispecific antibodies are harnessing the body's own immune system to recognize and destroy cancer cells with unprecedented precision. These new therapies are not only showing better efficacy in many cases but are also associated with more manageable side effect profiles, significantly improving patients' quality of life.
Therefore, get an overall knowledge on the further discussion of the current scenario of blood cancer, with a focus on genomic testing and the latest advancements in diagnosis and treatment. Listen to the insights shared by Dr. Abhay Bhave, absorb the shared knowledge, and follow Hidoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
In leukemia, allogeneic HCT is beneficial following primary induction failure.
2.
Team finds broken 'brake' on cancer mutation machine.
3.
Omega Fatty Acid Changes Tied to Lower Proliferation Rate in Early Prostate Cancer
4.
Prostate cancer screening program beneficial in top decile of polygenic risk score
5.
Talk About Medication Costs, Bringing Back Touch, and Understanding From Dish Tumors.
1.
New Research on Craniopharyngioma
2.
What Is May-Hegglin Anomaly? Understanding this Rare Blood Disorder
3.
A Closer Look at White Blood Cells in Urine: Uncovering the Causes and Treatments
4.
The Expanding Horizon of PSMA: A Comparative Clinical Review of Theranostics in Prostate Cancer and Beyond
5.
The Mysterious World of Petechiae: Exploring Causes and Treatments
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Complexities of Ph Negative ALL - Part VI
2.
A New Era in Managing Cancer-Associated Thrombosis
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V
4.
Navigating the Complexities of Ph Negative ALL - Part XV
5.
Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation